MorphoSys AG is further expanding its commercial operations in the US in anticipation of Food and Drug Administration approval of its first wholly-owned antibody therapeutic by the middle of 2020. The product, MOR208, is an Fc-engineered antibody directed against the cancer antigen CD19. It is being developed for diffuse large B cell lymphoma in patients with relapsed disease who are not eligible for high-dose chemotherapy or a stem cell transplant.
